 |
0 Companies | 0 Products |
|
|
0 Products | |
0 Diseases | |
0 Trials |  |
0 News |  |
| «12...7891011121314151617...199200» |
- | metformin / Generic mfg.
Preclinical, Journal: Brain Permeable AMP-Activated Protein Kinase Activator R481 Raises Glycaemia by Autonomic Nervous System Activation and Amplifies the Counterregulatory Response to Hypoglycaemia in Rats. (Pubmed Central) - Feb 16, 2022
We evaluated the efficacy of a novel brain permeable "metformin-like" AMP-activated protein kinase activator, R481, in regulating glucose homeostasis...Taken together, our data suggest that R481 amplifies the counterregulatory response to hypoglycemia by a central rather than a direct effect on the pancreatic α-cell. These data provide proof-of-concept that central AMPK could be a target for future drug development for prevention of hypoglycemia in diabetes.
- | Journal: Long non-coding RNA MEG3 inhibits neovascularization in diabetic retinopathy by regulating microRNA miR-6720-5p and cytochrome B5 reductase 2. (Pubmed Central) - Feb 16, 2022
The intervention of miR-6720-5p reversed the effect of MEG3 knockdown on hRMEC function, and this effect was eliminated by silencing CYB5R2. Therefore, MEG3 acted as a sponge to suppress miR-6720-5p and regulate the expression of CYB5R2, thereby inhibiting DR neovascularization.
- | Journal: Synthesis and application of carbon substrate nano material from biomass for surface protection - Effect of variables, electrochemical and isotherm studies. (Pubmed Central) - Feb 16, 2022
Tafel study confirmed the inhibitor examined as mixed type. Ch-NP demonstrated a high inhibitory effectiveness of 91% under the tested conditions and proved to be an effective alternative for industrial applications.
- | Journal: Enhancing robustness of halophilic aerobic granule sludge by granular activated carbon at decreasing temperature. (Pubmed Central) - Feb 16, 2022
The overexpression of the nitrogen assimilation gene glnA in heterotrophic bacteria (Halomonas and Marinobacterium) may promote the conversion of inorganic nitrogen to extracellular proteins to adapt to the decreased operational temperature. Our findings confirm that GAC addition is a simple but effective strategy to accelerate granulation and enhance the robustness of HAGS in saline wastewater treatment.
- | Journal: Study of antimycobacterial, cytotoxic, and mutagenic potential of polymeric nanoparticles of copper (II) complex. (Pubmed Central) - Feb 16, 2022
Particularly, PNs-NE30D demonstrated moderate inhibition of M. tuberculosis and low cytotoxic activity. None of the PNs induced mutagenicity.
- | Journal: Nitrogen removal performance of high ammonium and high salt wastewater by adding carbon source from food waste fermentation with different acidogenic metabolic pathways. (Pubmed Central) - Feb 16, 2022
In addition, the primary pathways of nitrogen removal were heterotrophic nitrification and denitrification, since the autotrophic nitrifiers were inhibited by the free ammonium and salinity. This study illustrated the differences of nitrogen removal performance and mechanisms with fermentation liquid components as carbon sources processing of HAHS wastewater.
- | Journal: Characterization of copper(II) specific pyridine containing ligands: Potential metallophores for Alzheimer's disease therapy. (Pubmed Central) - Feb 16, 2022
Direct fluorescence and reactive oxygen species (ROS) producing measurements prove that both ligands are able to remove Cu(II) from its amyloid-β complexes (CuAβ). Correlation was also established between the conditional stability constant of the Cu(II) complexes with different ligands and their ability of inhibition of ROS production by CuAβ.
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Retrospective data, Clinical Trial,Phase II, Journal: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. (Pubmed Central) - Feb 16, 2022
P2
This independent adjudication study identified lower AOE rates than previously reported, suggesting earlier overestimation that may inaccurately reflect AOE risk with ponatinib. This trial was registered under ClinicalTrials.gov identifier NCT01207440 on September 23, 2010 ( https://clinicaltrials.gov/ct2/show/NCT01207440 ).
- || Review, Journal: Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer. (Pubmed Central) - Feb 16, 2022
Based on the current overview of the key role of TAMs in drug resistance, we discuss the potential possibility for targeting TAMs to reduce drug resistance in BC treatment, By inhibiting the recruitment of TAMs, depleting the number of TAMs, regulating the polarization of TAMs and enhancing the phagocytosis of TAMs. Evidences in our review support it is important to develop novel therapeutic strategies to target TAMs in BC to overcome the treatment of resistance.
- | Daklinza (daclatasvir) / BMS
Preclinical, Journal: Influence of Piperine and Omeprazole on The Regional Absorption of Daclatasvir from Rabbit Intestine. (Pubmed Central) - Feb 16, 2022
This effect was inhibited by piperine. Co-administration of daclatasvir with omeprazole can enhance intestinal absorption a phenomenon which requires extension to human pharmacokinetic investigation.
- || Review, Journal: Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities. (Pubmed Central) - Feb 16, 2022
Many dual-target inhibitors have been developed using structural fusion, linkage, or library construction methods, overcoming the defects of many single-target inhibitors of PARP1 and achieving great success in clinical cancer therapy. This review summarizes the advance of dual-target PARP1 inhibitors in recent years, focusing on their structural optimization process, structure-activity relationships (SARs), and in vitro or in vivo analysis results.
- | Journal: Low-dimensional compounds containing bioactive ligands. Part XVII: Synthesis, structural, spectral and biological properties of hybrid organic-inorganic complexes based on [PdCl] with derivatives of 8-hydroxyquinolinium. (Pubmed Central) - Feb 16, 2022
Compounds 1 and 2 displayed selective and high cytotoxicity against human lung and breast cancer cells and showed moderate cytotoxicity against colon cancer cells. Accordingly, they might be auspicious candidates for future pharmacological investigations in lung and breast cancer research.
- | tetracycline / Generic mfg.
Journal: Effect of tetracycline on nitrogen removal in Moving Bed Biofilm Reactor (MBBR) System. (Pubmed Central) - Feb 16, 2022
At a TC concentration of 10 mg/L, there were also increases and decreases, respectively, in the abundance of resistance and denitrification functional genes. The inhibitory effect of TC on denitrification was achieved mainly by the inhibition of nitrite-reducing bacteria.
- | vancomycin / Generic mfg.
Preclinical, Journal: Fascaplysin derivatives binding to DNA via unique cationic five-ring coplanar backbone showed potent antimicrobial/antibiofilm activity against MRSA in vitro and in vivo. (Pubmed Central) - Feb 16, 2022
Among them, 14 and 18 are the most potent compounds with MIC value of 0.098 μg/ml (10-fold lower than vancomycin), and 18 featuring the lowest toxicity...Moreover, fascaplysins could inhibit MRSA biofilm formation in vitro and bacterial infection in vivo. All these results illustrate that fascaplysin derivative 18 is a strong and safe multi-target antibacterial agent, which makes it an attractive candidate for the treatment of MRSA and its biofilm infections.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Multiple targeted doxorubicin-lonidamine liposomes modified with p-hydroxybenzoic acid and triphenylphosphonium to synergistically treat glioma. (Pubmed Central) - Feb 16, 2022
In addition, Lip-CTPP could significantly prolong the survival time of glioma bearing mice, narrow the tumor region and inhibit the infiltration and metastasis capability of glioma cells. Collectively, Lip-CTPP are promising nano formulations to enhance the synergistic effect of DOX and LND in glioma treatment.
- || canertinib (CI-1033) / Pfizer, Gilotrif (afatinib) / Boehringer Ingelheim, Vizimpro (dacomitinib) / Pfizer
Clinical, Journal: Potential applications of clickable probes in EGFR activity visualization and prediction of EGFR-TKI therapy response for NSCLC patients. (Pubmed Central) - Feb 16, 2022
Moreover, 13 was applied to visualize EGFR mutant activity in tumour tissues from non-small-cell lung cancer (NSCLC) xenograft mouse models, and patients with NSCLC for the prediction of EGFR-TKI sensitivity. These results demonstrate that strategically designed EGFR-TKI-based probes allow discriminating EGFR mutations in human tissues and hold promise as useful diagnostic tools in predicting EGFR-TKI therapy response.
- | Journal: Design, synthesis and biological evaluation of P2-modified proline analogues targeting the HtrA serine protease in Chlamydia. (Pubmed Central) - Feb 16, 2022
Compound 49 resulted in approximately 9- and 22-fold improvement in the inhibitory potency and selectivity relative to 1, respectively. To date, compound 49 is the most potent HtrA inhibitor developed against Chlamydia spp.
- | Journal: Efficient targeted oncogenic KRAS degradation via first reversible-covalent PROTAC. (Pubmed Central) - Feb 16, 2022
Herein, we report the development of YF135, the first reversible-covalent PROTAC capable of recruiting VHL mediated proteasomal degradation of KRAS. YF135 induces the rapid and sustained degradation of endogenous KRAS and attenuates pERK signaling in H358 and H23 cells in a reversible manner.
- | Journal: Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold. (Pubmed Central) - Feb 16, 2022
Pharmacokinetic studies indicated that the oral bioavailability of compound 19k is 17.4%. These results demonstrate that compound 19k could serve as a novel lead compound for overcoming NTRK-fusion cancers.
- | Preclinical, Journal: Biocompatible silver(I) complexes with heterocyclic thioamide ligands for selective killing of cancer cells and high antimicrobial activity - A combined in vitro and in silico study. (Pubmed Central) - Feb 16, 2022
A moderate in vitro antioxidant capacity for free radicals scavenging was observed and a low potential to destroy the double-strand structure of calf-thymus DNA by intercalation, suggesting likely implication of these properties in the bioactivity mechanisms of these complexes. Further insight into possible mechanisms of bioactivity was obtained by molecular modeling calculations, by exploring their ability to act as potential inhibitors of DNA-gyrase, human estrogen receptor alpha, human cyclin-dependent kinase 6, and human papillomavirus E6 oncoprotein.
- | Journal: TAT-RHIM: a more complex issue than expected. (Pubmed Central) - Feb 16, 2022
Typical inhibitors of different forms of regulated cell death cannot impede this process, which appears to involve a direct disruption of biomembranes. Nevertheless, our finding has potential clinical relevance; reliable induction of a necrotic form of cell death distinct from all known forms of regulated cell death may offer a novel therapeutic approach to combat resistant tumour cells.
- || Review, Journal: Immunotherapy toxicity: identification and management. (Pubmed Central) - Feb 16, 2022
Using data from recent clinical trials, this review will focus on known IRAEs, particularly those seen in patients with breast cancer, and will summarize their prevalence, severity, and outcomes. We will discuss optimal strategies for early recognition and management, as well as approaches toward cautious retreatment following resolution of IRAEs.
- | fingolimod / Generic mfg.
Journal: MRSA-induced endothelial permeability and acute lung injury are attenuated by FTY720 S-phosphonate. (Pubmed Central) - Feb 16, 2022
In conclusion, Tys inhibits lung EC barrier disruption and proinflammatory signaling induced by MRSA in vitro and attenuates acute lung injury induced by MRSA in vivo. These results support the potential utility of Tys as a novel ARDS therapeutic strategy.
- | Journal: Overexpression of ultraconserved region 83- induces lung cancer tumorigenesis. (Pubmed Central) - Feb 16, 2022
We also show the oncogenic function of uc.83- is mediated by the phosphorylation of AKT and ERK 1/2, two important biomarkers of lung cancer cell proliferation. Based on our findings, inhibition against uc.83- could be a future therapeutic treatment for NSCLC to achieve simultaneous blockade of pathways involved in lung carcinogenesis.
- || Clinical, Journal: Intraarterial anti-leptin therapy via ICA protects ipsilateral CA1 neurons subjected to ischemia and reperfusion. (Pubmed Central) - Feb 16, 2022
Inhibition of leptin activity in hemispheric IR injury preserved the viability of ipsilateral hippocampal CA1 neurons, likely by preventing apoptosis and local inflammation. These results indicate that intraarterial anti-leptin therapy may have clinical potential in reducing hemispheric brain IR injury.
- | Journal: Alkbh1-mediated DNA N6-methyladenine modification regulates bone marrow mesenchymal stem cell fate during skeletal aging. (Pubmed Central) - Feb 16, 2022
These results indicate that intraarterial anti-leptin therapy may have clinical potential in reducing hemispheric brain IR injury. Our findings demonstrated that Alkbh1 regulated BMSCs fate and bone-fat balance during skeletal aging and provided a potential target for the treatment of osteoporosis.
- | Journal: N-terminal phosphorylation regulates the activity of Glycogen Synthase Kinase 3 from Plasmodium falciparum. (Pubmed Central) - Feb 16, 2022
By combining molecular modeling with experimental small-angle X-ray scattering data, we show that increased PfGSK3 activity is promoted by conformational changes in the PfGSK3 N‑terminus, triggered by N‑terminal phosphorylation. Our work provides novel insights into the structure and regulation of the malarial PfGSK3.
- | hyoscine butylbromide oral / Generic mfg.
Journal: Development of novel 2-aminoalkyl-6-(2-hydroxyphenyl)pyridazin-3(2H)-one derivatives as balanced multifunctional agents against Alzheimer's disease. (Pubmed Central) - Feb 16, 2022
Finally, in vivo study demonstrated that 12a, with suitable BBB permeability (log BB = -0.61), could efficaciously ameliorate cognitive dysfunction on scopolamine-treated mice by regulating cholinergic system and oxidative stress simultaneously. Altogether, these results highlight the potential of 12a as an innovative balanced multifunctional candidate for Alzheimer's disease treatment.
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Journal, Adverse events, PD(L)-1 Biomarker, IO biomarker: A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report. (Pubmed Central) - Feb 16, 2022
Increases in CTLA-4 and TIM-3 expression in CD4+ T cells (not CD8+), as well as an increase in Th17 cells, may reflect asthma-related inflammation activity. Immune-related adverse events during immune checkpoint inhibitor administration may be predictive markers of antitumor efficacy.
- | Journal: Early Detection of Prolonged Decreases in Maximal Voluntary Contraction Force after Eccentric Exercise of the Knee Extensors. (Pubmed Central) - Feb 16, 2022
The magnitude of decrease in MVIC strength at 1 to 3 d after ECC was associated with the magnitude of changes in RFD and MEP/MMAX immediately post-ECC. However, based on individual data, these markers were not sensitive for the practical detection of muscle damage.
- | Journal: IKKα plays a major role in canonical NF-kB signalling in colorectal cells. (Pubmed Central) - Feb 16, 2022
Notably, whilst IKKα loss strongly inhibited TNFα-dependent p65 nuclear translocation, IKKα and IKKβ contributed equally to c-Rel nuclear translocation indicating that different NF-κB subunits exhibit different dependencies on these IKKs. These results demonstrate a major role for IKKα in canonical NF-κB signalling in colorectal cells and may be relevant to efforts to design IKK inhibitors, which have focused largely on IKKβ to date.
- || Review, Journal: The Inhibition of RNA Viruses by Amaryllidaceae Alkaloids: Opportunities for the Development of Broad-Spectrum Anti-Coronavirus Drugs. (Pubmed Central) - Feb 16, 2022
Small molecules are well-suited to target the least-rapidly evolving structures within CoVs such as highly conserved RNA replication enzymes, and this renders them less vulnerable to evolved drug resistance. Examination of the vast literature describing the inhibition of RNA viruses by Amaryllidaceae alkaloids suggests that future, broad-spectrum anti-CoV drugs may be derived from this family of natural products.
- || Review, Journal: Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? (Pubmed Central) - Feb 16, 2022
Given the pharmacology of these monoclonal antibodies, their high interpatient pharmacokinetic variability, the actual clinical benefit as monotherapy that is observed only in a specific subset of patients, and the substantial cost of these treatments, a number of questions arise regarding the selected dose and the dosing interval. This review aims to outline the development of these immunotherapies and considers optimization options that could be used in clinical practice.
- | Journal: A multifunctional protective layer with biomimetic ionic channel suppressing dendrite and side reactions on zinc metal anodes. (Pubmed Central) - Feb 16, 2022
A full cell assembled with MnO cathode also displays improved long-term cycling performance (150 cycles at 200 mA g) when the Cu-GCN@Zn composite anode is applied. This work deepens our understanding of the kinetics of ion migration in the interface layer and paves the way for next-generation high energy-density Zn-metal batteries (ZMBs).
- | cisplatin / Generic mfg.
Journal: Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury. (Pubmed Central) - Feb 16, 2022
The potent renoprotective effects of 31c on AKI were confirmed by significant improvements in pathological kidney conditions in the mouse model. These results suggest that the novel PHD2/HDACs hybrid inhibitor, 31c, has a clinical potential as the renoprotective agent for the treatment/prevention of cisplatin-induced AKI for various cancers.
- | Journal, IO biomarker: Iridium(III) complexes entrapped in liposomes trigger mitochondria-mediated apoptosis and GSDME-mediated pyroptosis. (Pubmed Central) - Feb 16, 2022
The expression of Bcl-2 (B-cell lymphoma-2) family proteins was explored by western blot. The antitumor activity in vivo of Ir1Lipo was evaluated with an inhibitory rate of 53%.
- || Review, Journal: Bioprotection strategies in winemaking. (Pubmed Central) - Feb 16, 2022
In winemaking, there are commercial microbes currently under investigation, particularly with the aim to reduce or replace the use of sulphur dioxide. In this review, the potential of wine yeasts and lactic acid bacteria as bioprotection agents and their mechanisms of action during wine fermentation are presented.
- | nalidixic acid / Generic mfg., erythromycin / Generic mfg.
Journal: Prevalence of multidrug resistant Salmonella spp. in dairy products with the evaluation of the inhibitory effects of ascorbic acid, pomegranate peel extract, and D-tryptophan against Salmonella growth in cheese. (Pubmed Central) - Feb 16, 2022
Treatment of the artificially Salmonella-contaminated soft cheese with pomegranate peel extract, ascorbic acid, and D-tryptophan revealed a significant (P < 0.05) reduction in Salmonella growth in a dose-dependent manner. Therefore, the examined natural additives can be viewed as a promising new line of preservatives for dairy industry.
- | Journal: The estrogen receptor beta agonist liquiritigenin enhances the inhibitory effects of the cholesterol biosynthesis inhibitor RO 48-8071 on hormone-dependent breast-cancer growth. (Pubmed Central) - Feb 16, 2022
The anti-tumor properties of RO may in part be due to an off-target effect that reduces ERα and increases ERβ, the latter of which can then interact with LQ to promote anti-proliferative effects. The RO + LQ combination may have value when considering novel treatment strategies for hormone-dependent breast cancer.
- | Journal: Unprotected peptide macrocyclization and stapling via a fluorine-thiol displacement reaction. (Pubmed Central) - Feb 16, 2022
Pilot mechanism studies suggested that the uptake of FTDR-stapled peptides may involve multiple endocytosis pathways in a distinct pattern in comparison to peptides stapled by RCM. Consistent with the improved cell permeability, the FTDR-stapled lead Axin and p53 peptide analogues demonstrated enhanced inhibition of cancer cells over the RCM-stapled analogues and the unstapled peptides.
- | Journal: Two opposing hippocampus to prefrontal cortex pathways for the control of approach and avoidance behaviour. (Pubmed Central) - Feb 16, 2022
The superficial population is preferentially connected to widespread PFC inhibitory interneurons, and its activation promotes exploration; while the deep circuit is connected to PFC pyramidal neurons and fast spiking interneurons, and its activation promotes avoidance. Together this provides a mechanism for regulation of behaviour during approach avoidance conflict: through two specialized, parallel circuits that allow bidirectional hippocampal control of PFC.
- || sulindac / Generic mfg.
Clinical, Journal, HEOR: Sulindac Improves Stiffness and Quality of Life in Women Taking Aromatase Inhibitors for Breast Cancer. (Pubmed Central) - Feb 16, 2022
P2
Sulindac may relieve MSS in AI patients, especially physical function and stiffness. Randomized controlled trials should further evaluate NSAIDs on AI-MSS and AI adherence.
- | Preclinical, Journal: AgVI and Ag/ZnOVI nanostructures from Vateria indica (L.) exert antioxidant, antidiabetic, anti-inflammatory and cytotoxic efficacy on triple negative breast cancer cells in vitro. (Pubmed Central) - Feb 16, 2022
Additionally, the antioxidant and antidiabetic studies carried out have corroborated the radical scavenging and α-amylase inhibition capability up to 85.87 ± 0.001 and 89.60 ± 0.002 % respectively. Thus the overall results of the study substantiate the superlative antioxidant, antidiabetic, and antiproliferative property of green synthesized AgVI and Ag/ZnOVI nanostructures with excellent biocompatibility.
- || Clinical, Journal: Design and molecular insights of drug-active metabolite based co-amorphous formulation: a case study of toltrazuril-ponazuril co-amorphous. (Pubmed Central) - Feb 16, 2022
This could be attributed to the noticeably increased solid-state stabilization as well as inhibition of Pon on the crystallization of Tol from a supersaturated state. In general, our study provides some useful information and molecular insights to guide the development of drug-active metabolite-based co-amorphous formulations.
- | nifedipine immediate release / Generic mfg.
Journal: Hot-melt extruded hydroxypropyl methylcellulose acetate succinate based amorphous solid dispersions: Impact of polymeric combinations on supersaturation kinetics and dissolution performance. (Pubmed Central) - Feb 16, 2022
The in-vitro non-sink dissolution study revealed that although the binary nifedipine/HPMCAS-LG system had shown the greater supersaturation concentration of 66.1 µg/mL but could not maintain a supersaturation level up to 360 minutes. A synergistic effect emerged for ternary nifedipine/HPMCAS-LG/HPMCAS-HG, and nifedipine/HPMCAS-LG/Eudragit®FS100 systems maintained the supersaturation level with enhanced dissolution performance, demonstrating the potential of polymeric combinations for improved amorphous solid dispersion performance.
- | goserelin acetate / Generic mfg.
Preclinical, Journal: Goserelin/PLGA solid dispersion used to prepare long-acting microspheres with reduced initial release and reduced fluctuation of drug serum concentration in vivo. (Pubmed Central) - Feb 16, 2022
Pharmacodynamics study also showed potential effect of F5 microspheres on inhibiting the secretion of testosterone in male rats. HME-O/W method is potential to establish long-acting PLGA microspheres (loading water-soluble drug) , exhibiting stable drug serum concentration in vivo, and without large concentration fluctuation or serious pain/side effects.
- | Journal: CRISPR-Cas12a-regulated DNA adsorption and metallization on MXenes as enhanced enzyme mimics for sensitive colorimetric detection of hepatitis B virus DNA. (Pubmed Central) - Feb 16, 2022
Moreover, this colorimetric sensing strategy could be integrated with the smartphone platform to allow the visible sensitive detection of target DNA. Taken together, the proposed colorimetric method provides a novel approach for HBV DNA diagnosis, especially suitable for the high endemic, developing countries with limited instrumental and medical supports.
- | fluoxetine / Generic mfg.
Retrospective data, Journal: Dose-effect meta-analysis for psychopharmacological interventions using randomised data. (Pubmed Central) - Feb 16, 2022
The dose-effect meta-analysis enables clinicians to understand how the effect of a drug changes as a function of its dose. Such analysis should be conducted in practice using the one-stage model that incorporates evidence from all available studies.
- | Journal: Nuclear and mitochondrial DNA editing in human cells with zinc finger deaminases. (Pubmed Central) - Feb 16, 2022
Because ZFDs, unlike CRISPR-derived base editors, do not cleave DNA to yield single- or double-strand breaks, no unwanted indels caused by error-prone non-homologous end joining are produced at target sites. Furthermore, recombinant ZFD proteins, expressed in and purified from E. coli, penetrate cultured human cells spontaneously to induce targeted base conversions, demonstrating the proof-of-principle of gene-free gene therapy.
- || momelotinib (CYT 387) / Sierra Oncology
Clinical, Review, Journal: Momelotinib: an emerging treatment for myelofibrosis patients with anemia. (Pubmed Central) - Feb 16, 2022
Importantly, momelotinib may have overall survival benefits in frontline and second-line MF patients. MOMENTUM is an international registration-track phase 3 trial further assessing momelotinib's unique constellation of anemia and other benefits in second-line MF patients; the results of the MOMENTUM trial are keenly awaited and may lead to regulatory approval of momelotinib may lead to its approval.